- Home
- CERO vs ONCO Comparison
CERO vs ONCO Comparison
Compare CERO & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- ONCO
- Stock Information
- Founded
- CERO 2017
- ONCO 2018
- Country
- CERO United States
- ONCO United States
- Employees
- CERO N/A
- ONCO N/A
- Industry
- CERO
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- ONCO Health Care
- Exchange
- CERO Nasdaq
- ONCO Nasdaq
- Market Cap
- CERO 5.6M
- ONCO 1.8M
- IPO Year
- CERO N/A
- ONCO 2022
- Fundamental
- Price
- CERO $5.52
- ONCO $3.16
- Analyst Decision
- CERO Strong Buy
- ONCO
- Analyst Count
- CERO 2
- ONCO 0
- Target Price
- CERO $45.00
- ONCO N/A
- AVG Volume (30 Days)
- CERO 305.9K
- ONCO 45.9K
- Earning Date
- CERO 08-22-2025
- ONCO 08-14-2025
- Dividend Yield
- CERO N/A
- ONCO N/A
- EPS Growth
- CERO N/A
- ONCO N/A
- EPS
- CERO N/A
- ONCO N/A
- Revenue
- CERO N/A
- ONCO $1,326,959.00
- Revenue This Year
- CERO N/A
- ONCO N/A
- Revenue Next Year
- CERO N/A
- ONCO N/A
- P/E Ratio
- CERO N/A
- ONCO N/A
- Revenue Growth
- CERO N/A
- ONCO N/A
- 52 Week Low
- CERO $4.27
- ONCO $2.61
- 52 Week High
- CERO $895.40
- ONCO $552.50
- Technical
- Relative Strength Index (RSI)
- CERO 34.97
- ONCO 52.40
- Support Level
- CERO $5.29
- ONCO $3.00
- Resistance Level
- CERO $5.65
- ONCO $3.32
- Average True Range (ATR)
- CERO 0.53
- ONCO 0.16
- MACD
- CERO -0.07
- ONCO 0.08
- Stochastic Oscillator
- CERO 34.19
- ONCO 75.74
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.